-
1
-
-
79551559557
-
Clinical practice. Gout
-
Neogi T,. Clinical practice. Gout. N Engl J Med, 2011; 364: 443-452.
-
(2011)
N Engl J Med
, vol.364
, pp. 443-452
-
-
Neogi, T.1
-
2
-
-
84869186940
-
American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
-
Khanna D, Fitzgerald JD, Khanna PP, et al,. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012; 64: 1431-1446.
-
(2012)
Arthritis Care Res (Hoboken)
, vol.64
, pp. 1431-1446
-
-
Khanna, D.1
Fitzgerald, J.D.2
Khanna, P.P.3
-
3
-
-
0037449776
-
An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition
-
Okamoto K, Eger BT, Nishino T, et al,. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem, 2003; 278: 1848-1855.
-
(2003)
J Biol Chem
, vol.278
, pp. 1848-1855
-
-
Okamoto, K.1
Eger, B.T.2
Nishino, T.3
-
4
-
-
13444257733
-
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
-
Takano Y, Hase-Aoki K, Horiuchi H, et al,. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005; 76: 1835-1847.
-
(2005)
Life Sci
, vol.76
, pp. 1835-1847
-
-
Takano, Y.1
Hase-Aoki, K.2
Horiuchi, H.3
-
5
-
-
17144396355
-
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment
-
Mayer MD, Khosravan R, Vernillet L, et al,. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther, 2005; 12: 22-34.
-
(2005)
Am J Ther
, vol.12
, pp. 22-34
-
-
Mayer, M.D.1
Khosravan, R.2
Vernillet, L.3
-
6
-
-
29644447615
-
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
-
Khosravan R, Grabowski BA, Mayer MD, et al,. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol, 2006; 46: 88-102.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 88-102
-
-
Khosravan, R.1
Grabowski, B.A.2
Mayer, M.D.3
-
7
-
-
81755187321
-
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: Pharmacokinetic and pharmacodynamic study
-
Tatsuo H, Iwao O,. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol, 2011; 17: S27-S34.
-
(2011)
J Clin Rheumatol
, vol.17
-
-
Tatsuo, H.1
Iwao, O.2
-
8
-
-
0022358953
-
Aplastic anemia in a patient with end-stage renal disease caused by allopurinol
-
Matsushita K, Ikegami K, Fukui H,. Aplastic anemia in a patient with end-stage renal disease caused by allopurinol. Nihon Jinzo Gakkai Shi, 1985; 27: 1333-1337.
-
(1985)
Nihon Jinzo Gakkai Shi
, vol.27
, pp. 1333-1337
-
-
Matsushita, K.1
Ikegami, K.2
Fukui, H.3
-
9
-
-
64549126581
-
Allopurinol-induced aplastic anemia in a patient with chronic kidney disease
-
Kim YW, Park BS, Ryu CH, et al,. Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clin Nephrol, 2009; 71: 203-206.
-
(2009)
Clin Nephrol
, vol.71
, pp. 203-206
-
-
Kim, Y.W.1
Park, B.S.2
Ryu, C.H.3
-
10
-
-
74549210268
-
Advances in the treatment of neutropenia
-
Dale DC,. Advances in the treatment of neutropenia. Curr Opin Support Palliat Care, 2009; 3: 207-212.
-
(2009)
Curr Opin Support Palliat Care
, vol.3
, pp. 207-212
-
-
Dale, D.C.1
-
11
-
-
34248372109
-
Systematic review: Agranulocytosis induced by nonchemotherapy drugs
-
Andersohn F, Konzen C, Garbe E,. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med, 2007; 146: 657-665.
-
(2007)
Ann Intern Med
, vol.146
, pp. 657-665
-
-
Andersohn, F.1
Konzen, C.2
Garbe, E.3
-
12
-
-
79955050820
-
Clinical presentation and management of drug-induced agranulocytosis
-
Andres E, Zimmer J, Mecili M, et al,. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol, 2011; 4: 143-151.
-
(2011)
Expert Rev Hematol
, vol.4
, pp. 143-151
-
-
Andres, E.1
Zimmer, J.2
Mecili, M.3
-
13
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
-
14
-
-
0029833339
-
Immune mechanisms leading to drug-induced blood dyscrasias
-
Claas FH,. Immune mechanisms leading to drug-induced blood dyscrasias. Eur J Haematol Suppl, 1996; 60: 64-68.
-
(1996)
Eur J Haematol Suppl
, vol.60
, pp. 64-68
-
-
Claas, F.H.1
-
15
-
-
0035175936
-
Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-jewish caucasian sample
-
Dettling M, Cascorbi I, Roots I, et al,. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. Arch Gen Psychiatry, 2001; 58: 93-94.
-
(2001)
Arch Gen Psychiatry
, vol.58
, pp. 93-94
-
-
Dettling, M.1
Cascorbi, I.2
Roots, I.3
-
16
-
-
70249122727
-
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
-
Tassaneeyakul W, Jantararoungtong T, Chen P, et al,. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics, 2009; 19: 704-709.
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 704-709
-
-
Tassaneeyakul, W.1
Jantararoungtong, T.2
Chen, P.3
-
17
-
-
80052596861
-
Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis
-
Somkrua R, Eickman EE, Saokaew S, et al,. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet, 2011; 12: 118.
-
(2011)
BMC Med Genet
, vol.12
, pp. 118
-
-
Somkrua, R.1
Eickman, E.E.2
Saokaew, S.3
-
18
-
-
34248655834
-
Idiosyncratic drug-induced agranulocytosis: Update of an old disorder
-
Andres E, Zimmer J, Affenberger S, et al,. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med, 2006; 17: 529-535.
-
(2006)
Eur J Intern Med
, vol.17
, pp. 529-535
-
-
Andres, E.1
Zimmer, J.2
Affenberger, S.3
-
19
-
-
0022339994
-
Drug-induced agranulocytosis: Evidence for the commitment of bone marrow haematopoiesis
-
Heit W, Heimpel H, Fischer A, et al,. Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis. Scand J Haematol, 1985; 35: 459-468.
-
(1985)
Scand J Haematol
, vol.35
, pp. 459-468
-
-
Heit, W.1
Heimpel, H.2
Fischer, A.3
|